Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain.
Cannabinoid CB1 and CB2 receptors are located at key sites involved in the relaying and processing of noxious inputs. Both CB1 and CB2 receptor agonists have analgesic effects in a range of models of inflammatory and neuropathic pain. Importantly, clinical trials of cannabis-based medicines indicate that the pre-clinical effects of cannabinoid agonists may translate into therapeutic potential in humans. One of the areas of concern with this pharmacological approach is that CB1 receptors have a widespread distribution in the brain and that global activation of CB1 receptors is associated with adverse side effects. Studies of the endogenous cannabinoids (endocannabinoids) have demonstrated that they are present in most tissues and that in some pain states, such as neuropathic pain, levels of endocannabinoids are elevated at key sites involved in pain processing. An alternative approach that can be used to harness the potential therapeutic effects of cannabinoids is to maximise the effects of the endocannabinoids, the actions of which are terminated by re-uptake and metabolism by various enzymes, including fatty acid amide hydrolase (FAAH), monoacylglycerol lipase (MAGL) and cyclooxygenase type 2 (COX2). Preventing the metabolism, or uptake, of endocannabinoids elevates levels of these lipid compounds in tissue and produces behavioural analgesia in models of acute pain. Herein we review recent studies of the effects of inhibition of metabolism of endocannabinoids versus uptake of endocannabinoids on nociceptive processing in models of inflammatory and neuropathic pain.
Jhaveri
M D
MD
School of Biomedical Sciences, Institute of Neuroscience, Queens Medical Centre, Nottingham, UK. maulik.jhaveri@nottingham.ac.uk
Richardson
D
D
Chapman
V
V
D000818:Animals; D063387:Cannabinoid Receptor Antagonists; D063385:Cannabinoid Receptor Modulators / Q000378:metabolism* / Q000493:pharmacokinetics; D063388:Endocannabinoids; D006801:Humans; D007249:Inflammation / Q000378:metabolism / Q000503:physiopathology* / Q000517:prevention & control; D008954:Models, Biological; D010146:Pain / Q000378:metabolism / Q000503:physiopathology* / Q000517:prevention & control; D043882:Receptors, Cannabinoid / Q000502:physiology
D063387:Cannabinoid Receptor Antagonists; D063385:Cannabinoid Receptor Modulators; D063388:Endocannabinoids; D043882:Receptors, Cannabinoid
Nature. 1996 Nov 7;384(6604):83-7
8900284
Biochem Biophys Res Commun. 1995 Oct 4;215(1):89-97
7575630
J Biol Chem. 2005 Sep 9;280(36):31405-12
15987694
J Pharmacol Exp Ther. 2006 Jun;317(3):1365-71
16510698
Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10821-6
15247426
Eur J Neurosci. 2004 Nov;20(9):2311-20
15525273
Br J Pharmacol. 2006 Feb;147(3):281-8
16331291
Biochem Pharmacol. 2003 May 1;65(9):1473-81
12732359
Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9371-6
11470906
J Pharmacol Exp Ther. 2005 Mar;312(3):1161-9
15572651
J Pharmacol Exp Ther. 2005 Apr;313(1):352-8
15579492
J Med Chem. 2001 Dec 20;44(26):4505-8
11741470
Br J Pharmacol. 2002 Oct;137(4):413-20
12359622
Pain. 2004 May;109(1-2):124-31
15082134
Life Sci. 2005 Aug 19;77(14):1584-604
15979096
J Neurosci. 2006 Dec 20;26(51):13318-27
17182782
Prostaglandins Other Lipid Mediat. 2002 Aug;68-69:521-34
12432941
Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10529-33
12917492
J Med Chem. 1999 Mar 11;42(5):896-902
10072686
J Med Invest. 1998 Aug;45(1-4):27-36
9864962
Nature. 2005 Jun 23;435(7045):1108-12
15973410
J Biol Chem. 1997 Aug 22;272(34):21181-6
9261124
J Neurosci. 2007 Mar 14;27(11):2883-9
17360910
Eur J Neurosci. 2005 Jul;22(2):371-9
16045490
Biochem Pharmacol. 1999 Feb 15;57(4):417-23
9933030
J Biol Chem. 2005 May 6;280(18):18488-97
15749716
J Biol Chem. 2000 Oct 27;275(43):33744-9
10931854
Microvasc Res. 2005 Jan;69(1-2):28-35
15797258
J Biol Chem. 2002 Jun 28;277(26):23278-86
11956198
J Neurosci. 2004 Mar 17;24(11):2727-32
15028765
Pharmacol Biochem Behav. 2006 Apr;83(4):508-16
16647109
Biochemistry. 2003 Aug 5;42(30):9041-9
12885237
Brain Res Rev. 2006 Sep;52(2):201-43
16647138
J Neurosci. 2001 Aug 15;21(16):5847-53
11487607
Eur J Pharmacol. 2000 May 19;396(2-3):85-92
10822060
Reg Anesth Pain Med. 2005 Jul-Aug;30(4):351-5
16032587
Pain. 2002 Apr;96(3):253-260
11972997
Neuropharmacology. 2005 Apr;48(5):658-72
15814101
Eur J Pharmacol. 2006 Nov 21;550(1-3):68-77
17027744
J Neurochem. 2000 Jun;74(6):2597-606
10820223
Biochem Pharmacol. 2001 Sep 1;62(5):517-26
11585048
Biochem J. 2000 Nov 1;351 Pt 3:817-24
11042139
Pharmacol Res. 2006 Dec;54(6):481-5
16997568
Biochem J. 2004 May 15;380(Pt 1):265-72
14969584
Pharmacol Rev. 2006 Sep;58(3):389-462
16968947
Neuroscience. 2003;119(3):747-57
12809695
Neuropharmacology. 2005 Jun;48(8):1072-8
15910883
J Med Chem. 2003 Apr 10;46(8):1512-22
12672252
Br J Pharmacol. 2006 Aug;148(7):1022-32
16770320
FEBS Lett. 1998 Jan 23;422(1):69-73
9475172
Biochemistry. 2001 Jan 30;40(4):861-6
11170406
Biochemistry. 2004 Jun 29;43(25):8184-90
15209515
J Immunol. 2003 May 15;170(10):4953-62
12734338
Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8400-5
12060783
Cardiovasc Drug Rev. 2004 Summer;22(2):103-20
15179448
FEBS Lett. 2000 Feb 25;468(2-3):176-80
10692582
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4269-74
12655057
Eur J Pharmacol. 2005 Dec 28;528(1-3):65-72
16316650
J Biol Chem. 2002 Nov 22;277(47):44877-85
12244105
Br J Pharmacol. 2007 Mar;150(6):693-701
17179944
AAPS J. 2006;8(2):E409-12
16808043
J Pharmacol Exp Ther. 2007 Jul;322(1):236-42
17412883
J Dermatol Sci. 2005 Jun;38(3):177-88
15927811
Pain. 2006 Dec 15;126(1-3):102-14
16844297
Pharmacol Ther. 2002 Aug;95(2):127-35
12182960
Biochem Pharmacol. 2005 Aug 1;70(3):446-52
15963472
Biochem Pharmacol. 1995 Jun 29;50(1):83-90
7605349
Neuroscience. 2003;117(3):659-70
12617970
Prog Neurobiol. 2001 Apr;63(5):569-611
11164622
Biochem Biophys Res Commun. 2000 Nov 30;278(3):576-83
11095952
Pain. 2005 Dec 5;118(3):327-335
16289798
Science. 1992 Dec 18;258(5090):1946-9
1470919
J Pharmacol Exp Ther. 2006 Mar;316(3):969-82
16284279
Pharmacol Ther. 2004 Nov;104(2):117-35
15518883
Nat Neurosci. 2007 Jul;10(7):870-9
17558404
AAPS J. 2006 Nov 17;8(4):E693-708
17233533
Nat Med. 2003 Jan;9(1):76-81
12461523
J Enzyme Inhib Med Chem. 2003 Feb;18(1):55-8
12751821
J Physiol. 2006 May 1;572(Pt 3):735-45
16484297
Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10819-24
12136125
Neuropharmacology. 2007 Feb;52(2):415-22
17011598
Eur J Pharmacol. 2005 Jan 31;508(1-3):139-46
15680264
Br J Pharmacol. 2001 Jun;133(4):513-20
11399668
Eur J Pharmacol. 2007 Jan 5;554(1):12-7
17112505
Br J Pharmacol. 2006 May;148(1):102-13
16501580
Br J Pharmacol. 2007 Jan;150(2):186-91
17143303
Eur J Pharmacol. 2003 Mar 19;464(2-3):229-35
12620517
Anesthesiology. 2003 Oct;99(4):955-60
14508331
Annu Rev Pharmacol Toxicol. 2002;42:553-83
11807183
Mol Pharmacol. 2001 Jun;59(6):1369-75
11353795
Br J Pharmacol. 2002 Nov;137(6):837-44
12411415
Curr Pharm Des. 2004;10(6):659-67
14965328
Br J Pharmacol. 2007 Mar;150(6):766-81
17279090
Biochem J. 1997 Mar 1;322 ( Pt 2):671-7
9065792
Drug Alcohol Depend. 1996 Nov;42(3):201-7
8912803
Eur J Pharmacol. 2002 Aug 2;449(1-2):99-103
12163112
J Neurobiol. 2004 Oct;61(1):149-60
15362158
Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3376-80
7724569
Br J Pharmacol. 2005 Oct;146(3):467-76
16100529
FASEB J. 2006 Mar;20(3):568-70
16403786
Nature. 1998 Jul 16;394(6690):277-81
9685157
J Med Chem. 1996 Oct 25;39(22):4515-9
8893848
Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):12198-203
10518599
J Biol Chem. 2001 Aug 10;276(32):30072-7
11402053
J Pharmacol Exp Ther. 2004 Nov;311(2):441-8
15229230
Brain Res. 1998 Feb 16;784(1-2):329-36
9518675
Prog Neuropsychopharmacol Biol Psychiatry. 2004 Aug;28(5):849-63
15363608
Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8756-61
15138300
J Pharmacol Exp Ther. 1997 Dec;283(3):1069-75
9399978
Eur J Neurosci. 2006 Oct;24(7):2011-20
17040473
J Lipid Res. 2004 Apr;45(4):757-63
14729864
Pain. 2001 Sep;93(3):239-245
11514083